Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating restated by investment analysts at Bank of America Corporation in a research report issued to clients and investors on Friday. They presently have a $593.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $589.00. Bank of America Corporation’s target price suggests a potential upside of 13.79% from the company’s previous close.

REGN has been the subject of several other reports. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a research report on Monday, May 15th. Vetr lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target for the company. in a research note on Monday, April 24th. UBS AG set a $489.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Finally, Canaccord Genuity set a $484.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, June 20th. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating and thirteen have given a buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $463.03.

Shares of Regeneron Pharmaceuticals (REGN) traded down 0.82% during trading on Friday, hitting $516.86. 258,031 shares of the stock were exchanged. The stock’s 50 day moving average price is $493.24 and its 200 day moving average price is $413.36. The firm has a market capitalization of $54.57 billion, a price-to-earnings ratio of 62.57 and a beta of 1.67. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm’s revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.57 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals will post $12.77 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Given Buy Rating at Bank of America Corporation” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/21/regeneron-pharmaceuticals-inc-regn-given-buy-rating-at-bank-of-america-corporation-2.html.

In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the sale, the senior vice president now directly owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Sanofi purchased 136,050 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were purchased at an average cost of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 59,396 shares of company stock valued at $28,484,734. 10.40% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Korea Investment CORP raised its stake in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the last quarter. FNY Managed Accounts LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $140,000. Alpha Windward LLC raised its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the last quarter. Wendell David Associates Inc. purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $204,000. Finally, Welch & Forbes LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $211,000. 66.87% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.